Calendar

Week of Jan 30, 2023

Jan 31, 2023approval1290d agoIMATINIB MESYLATE — FDA approvalInhibikase Therapeutics, Inc.

Sponsor: EUGIA PHARMA. Form: TABLET. Route: ORAL

Jan 31, 2023approval1290d agoIMATINIB MESYLATE — FDA approvalInhibikase Therapeutics, Inc.

Sponsor: EUGIA PHARMA. Form: TABLET. Route: ORAL

Jan 31, 2023approval1290d agoIMATINIB MESYLATE — FDA approvalInhibikase Therapeutics, Inc.

Sponsor: EUGIA PHARMA. Form: TABLET. Route: ORAL

Jan 31, 2023approval1290d agoIMATINIB MESYLATE — FDA approvalInhibikase Therapeutics, Inc.

Sponsor: EUGIA PHARMA. Form: TABLET. Route: ORAL

Jan 31, 2023approval1290d agoBREXPIPRAZOLE — FDA approvalBREXPIPRAZOLE

Sponsor: AMNEAL. Form: TABLET. Route: ORAL

Jan 31, 2023approval1290d agoSYNAREL (NAFARELIN ACETATE) — FDA approvalnafarelin acetate

Sponsor: PFIZER. Form: SPRAY, METERED. Route: NASAL

Feb 1, 2023approval1289d agoTEZSPIRE (TEZEPELUMAB-EKKO) — FDA approvaltezepelumab

Sponsor: ASTRAZENECA AB. Form: SOLUTION. Route: SUBCUTANEOUS

Feb 2, 2023approval1288d agoVORICONAZOLE — FDA approvalVORICONAZOLE

Sponsor: MEITHEAL. Form: POWDER. Route: INTRAVENOUS

Feb 2, 2023approval1288d agoVORICONAZOLE — FDA approvalVORICONAZOLE

Sponsor: MEITHEAL. Form: POWDER. Route: INTRAVENOUS

Feb 3, 2023approval1287d agoAFREZZA (INSULIN RECOMBINANT HUMAN) — FDA approvalinsulin human

Sponsor: MANNKIND. Form: POWDER. Route: INHALATION

Feb 6, 2023approval1284d agoSYNJARDY XR (EMPAGLIFLOZIN) — FDA approval(empagliflozin + metformin hydrochloride ER)

Sponsor: BOEHRINGER INGELHEIM. Form: TABLET, EXTENDED RELEASE. Route: ORAL

Feb 6, 2023

Feb 13, 2023approval1277d agoCABOMETYX (CABOZANTINIB S-MALATE) — FDA approvalcabozantinib s-malate

Sponsor: EXELIXIS INC. Form: TABLET. Route: ORAL

Feb 14, 2023approval

page 8 of 510